Northwire Canada EditionTuesday, July 14, 2026
Sign inSubscribe
Northwire
⌕
WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8% WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8%
Financings

Rocket Doctor AI Announces $2.049 Million Gross Proceeds from Warrant Exercises

By The Northwire Desk — AI Analysis Mar 17, 2026 · 08:00 AIDR · 0.66 Rocket Doctor AI Inc.
AIDR · Price

Executive Summary

  • Rocket Doctor AI reported the exercise of 3,242,030 common share purchase warrants at CAD $0.60 each, generating approximately CAD $1.95 million in gross proceeds.
  • An additional 172,866 warrants issued in connection with debt settlement units were exercised, adding roughly CAD $0.10 million to proceeds.
  • Total aggregate gross proceeds from all warrant exercises amount to approximately CAD $2.05 million, which will be used for working capital and general corporate purposes to support the company’s AI‑powered healthcare expansion in North America.

Key Details

  • Warrant Exercise Volume: 3,242,030 warrants (July 5 2024 – Mar 13 2026) at CAD $0.60 per warrant → CAD $1,945,218 gross proceeds.
  • Debt‑Settlement Warrants: 172,866 warrants (issued Apr 5 2024, expiring Apr 5 2026) exercised at CAD $0.60 each → CAD $103,720 gross proceeds.
  • Total Gross Proceeds: Approximately CAD $2,048,938 from all warrant exercises.
  • Recent Activity: 2,054,224 warrants exercised in the three months prior to Mar 13 2026, generating about CAD $1,232,535.
  • Original Issuance: Warrants were issued on Mar 13 2024 as part of a private placement financing and converted on Jun 21 2024; they expire on Mar 13 2026.
  • Use of Proceeds: Funds will be allocated to working capital and general corporate purposes, supporting continued expansion of AI‑driven healthcare solutions across North America and the 2026 U.S. growth plan.

Notable Quotes

“The exercise of these warrants reflects continued confidence in Rocket Doctor AI’s strategy and long‑term vision,” said Dr. Essam Hamza, CEO.
“We appreciate the ongoing support from our shareholders as we continue to expand our AI‑powered healthcare platform and focus on our 2026 U.S. growth plans.”

Read the original news release →

More from Rocket Doctor AI Inc.

Jun 30, 2026 · 08:00

Rocket Doctor Enters into a Primary Care Value-Based Care Agreement in the United States, Expanding In-Network Coverage by More Than 5 Million Members

M&A / Property Jun 23, 2026 · 08:00

AI-driven telemedicine platform expanding U.S. payer network, but burning cash with a going concern warning.

M&A / Property Jun 18, 2026 · 08:00

AI-driven telehealth platform scaling U.S. payer network, but burning cash and diluting equity to fund marketing.

M&A / Property Jun 16, 2026 · 08:00

AI-driven telehealth platform scaling U.S. payer access while burning cash to fund growth and R&D.

Other Jun 08, 2026 · 08:00

Rocket Doctor AI Launches a Strategic Marketing Partnership with Rick Ware Racing and FINTEKK AP for the 2026 NASCAR Cup Series, NHRA (National Hot Rod Association), World Supercross Championship, AFT (AMA - American Flat Track) and other Nationally telev

M&A / Property Jun 02, 2026 · 08:00

AI Virtual Care Platform Accelerates U.S. Visits and Secures Cash Runway, But Margin Compression and Going Concern Doubts Loom

Earnings